Hormonal
GLP-1 receptor agonists (GLP-1RA) significantly reduce major adverse cardiovascular events (MACE), all-cause mortality, and heart failure hospitalizations in patients with type 2 diabetes and obesity, with specific benefits observed in heart failure with preserved ejection fraction (HFpEF).
If you have Type 2 Diabetes and Obesity, especially with heart issues, GLP-1 medications like Semaglutide or Liraglutide are highly effective. They not only help with weight loss but significantly reduce the risk of heart attacks, strokes, and heart failure hospitalizations. While injections can cause temporary stomach issues, the long-term protection for your heart is substantial. Discuss these options with your doctor, particularly if you have heart failure with preserved ejection fraction.
Дослідження безпеки використання агоністів GLP-1R для серцево-судинних захворювань продемонстрували зниження смертності від усіх причин і серцево-судинної смертності, а також нижчі показники серйозних серцево-судинних подій, зокрема інсульту та інфаркту міокарда.
Why this rating
The paper cites multiple large-scale randomized controlled trials (CVOTs) and meta-analyses (e.g., STEP HFpEF, SELECT) with thousands of participants.
Source
Агоністи рецепторів глюкагоноподібного пептиду-1 у лікуванні захворювань серцево-судинної системи в пацієнтів із цукровим діабетом
A.M. Sokolova et al. · Ukrainian Journal of Cardiology · 2025
DOI 10.31928/2664-4479-2025.3.7182
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →